EMERYVILLE, Calif., March 14 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI) announced today the appointment of Louis Drapeau, to the company's Board of Directors. Mr. Drapeau has extensive financial management experience with emerging pharmaceutical and life science companies.
"We are quite excited to have access to Lou's expertise," said Isaac Cohen, O.M.D., Bionovo's Chairman and CEO. "Lou is particularly well versed in the unique financial scenarios which face emerging life science companies. He is a 'financial expert' in the truest sense of the term. His experience with public markets, regulation and financial deal structures in the biopharma industry will support Bionovo's rapid growth and optimize its potential."
"I find Bionovo's pipeline of drugs and innovative technologies to be unique and novel in the biopharmaceutical industry, working towards safe and efficacious treatments for significant unmet medical needs," said Mr. Drapeau. "From my experience working with a number of emerging companies, I believe that Bionovo is at a critical value inflection point, with exciting potential for patients and shareholders."
Louis Drapeau currently serves as the Chief Financial Officer of InSite
Vision, having been appointed to that position on October 1, 2007. Prior to
InSite Vision, he served as Chief Financial Officer, Senior Vice President,
Finance, at Nektar Therapeutics, a biopharmaceutical company headquartered
in San Carlos, Calif. from January 2006 to August 2007. Prior to Nektar, he
served as Acting Chief Executive Officer from August 2004 to May 2005 and
as Senior Vice President and Chief Financial Officer from August 2002 to
August 2005 for BioMarin Pharmaceutical Inc. Previously, Drapeau spent 30
|SOURCE Bionovo, Inc.|
Copyright©2008 PR Newswire.
All rights reserved